[
  {
    "bcr_patient_uuid": "83b3060c-2449-4581-88ef-817d126e4525",
    "patient_ID": "TCGA.KL.8323",
    "bcr_drug_barcode": "TCGA-KL-8323-D33911",
    "bcr_drug_uuid": "5EDBDBA5-8EE3-45E6-B0A5-5948DA3689A5",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "LYMPHOCYTE INFUSION",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 880,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "83b3060c-2449-4581-88ef-817d126e4525",
    "patient_ID": "TCGA.KL.8323",
    "bcr_drug_barcode": "TCGA-KL-8323-D33912",
    "bcr_drug_uuid": "69C8BF63-23C1-46D5-AFB8-7192AFB58760",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "PTK-ZK",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 911,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 942,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "63643ba6-bed9-4c36-91dd-a18105fadc06",
    "patient_ID": "TCGA.KL.8336",
    "bcr_drug_barcode": "TCGA-KL-8336-D33939",
    "bcr_drug_uuid": "C706BEA1-7CC9-4D8A-ABCC-51DD05EFE077",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 138,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "63643ba6-bed9-4c36-91dd-a18105fadc06",
    "patient_ID": "TCGA.KL.8336",
    "bcr_drug_barcode": "TCGA-KL-8336-D33940",
    "bcr_drug_uuid": "6251213A-2CA9-4E23-BB20-356074A881A8",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 558,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 817,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "63643ba6-bed9-4c36-91dd-a18105fadc06",
    "patient_ID": "TCGA.KL.8336",
    "bcr_drug_barcode": "TCGA-KL-8336-D33941",
    "bcr_drug_uuid": "74B0A250-2C27-49BB-9ED5-9E2994C6CF9A",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 824,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 838,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e0e38071-877f-4ebf-955f-483eb4865351",
    "patient_ID": "TCGA.KL.8339",
    "bcr_drug_barcode": "TCGA-KL-8339-D32704",
    "bcr_drug_uuid": "C00D326B-2D48-4084-9F21-5C04D5E27BC9",
    "form_completion_date": "2012-6-7",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 111,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 251,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "70e306ee-9584-49d6-81a1-a49d837ab6aa",
    "patient_ID": "TCGA.KL.8341",
    "bcr_drug_barcode": "TCGA-KL-8341-D33919",
    "bcr_drug_uuid": "6463DA70-D7C2-4BB5-84E9-6C5AACDD0E94",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 196,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 366,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "70e306ee-9584-49d6-81a1-a49d837ab6aa",
    "patient_ID": "TCGA.KL.8341",
    "bcr_drug_barcode": "TCGA-KL-8341-D33922",
    "bcr_drug_uuid": "D4BBFA8D-71E0-4F62-B628-C833F75DFDE9",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 196,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 366,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "70e306ee-9584-49d6-81a1-a49d837ab6aa",
    "patient_ID": "TCGA.KL.8341",
    "bcr_drug_barcode": "TCGA-KL-8341-D33923",
    "bcr_drug_uuid": "AC4D913B-061E-41B9-A504-8E63C9A93D00",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 397,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 457,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "70e306ee-9584-49d6-81a1-a49d837ab6aa",
    "patient_ID": "TCGA.KL.8341",
    "bcr_drug_barcode": "TCGA-KL-8341-D33924",
    "bcr_drug_uuid": "E922EBC8-97A1-4B90-8D38-5CDD480BE0D5",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 567,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 609,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "70e306ee-9584-49d6-81a1-a49d837ab6aa",
    "patient_ID": "TCGA.KL.8341",
    "bcr_drug_barcode": "TCGA-KL-8341-D33925",
    "bcr_drug_uuid": "6C137653-E683-420B-B63B-F2C57B064041",
    "form_completion_date": "2012-7-24",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 624,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23656226-2d99-4548-959f-5c2eed803e33",
    "patient_ID": "TCGA.KM.8438",
    "bcr_drug_barcode": "TCGA-KM-8438-D32859",
    "bcr_drug_uuid": "1574D627-CF11-42BA-94C3-3F5854A4C649",
    "form_completion_date": "2012-6-14",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2342,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2731,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23656226-2d99-4548-959f-5c2eed803e33",
    "patient_ID": "TCGA.KM.8438",
    "bcr_drug_barcode": "TCGA-KM-8438-D32860",
    "bcr_drug_uuid": "2D6C5401-74D1-4080-B9FD-8C94D19C5A99",
    "form_completion_date": "2012-6-14",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2731,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 4436,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23656226-2d99-4548-959f-5c2eed803e33",
    "patient_ID": "TCGA.KM.8438",
    "bcr_drug_barcode": "TCGA-KM-8438-D32861",
    "bcr_drug_uuid": "6442C5A4-A38C-487D-95A2-9BD3EB249787",
    "form_completion_date": "2012-6-14",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 3554,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3858,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8D30C7BE-73B6-4C4C-80C5-31152B2F7CB0",
    "patient_ID": "TCGA.KM.A7Q8",
    "bcr_drug_barcode": "TCGA-KM-A7Q8-D62492",
    "bcr_drug_uuid": "3789FA17-816C-4768-A1FE-E8E49373B5BC",
    "form_completion_date": "2014-7-21",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b08dfba8-6afb-4217-9259-72be6f1f3363",
    "patient_ID": "TCGA.KN.8426",
    "bcr_drug_barcode": "TCGA-KN-8426-D34188",
    "bcr_drug_uuid": "36E267F1-1DC3-404E-830B-B58767C04AA0",
    "form_completion_date": "2012-8-10",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b08dfba8-6afb-4217-9259-72be6f1f3363",
    "patient_ID": "TCGA.KN.8426",
    "bcr_drug_barcode": "TCGA-KN-8426-D39303",
    "bcr_drug_uuid": "6330F707-EA10-4F3C-916C-3C0292CD7E85",
    "form_completion_date": "2013-1-16",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "455fd7d4-5ff4-423f-83ce-4630aef89bb7",
    "patient_ID": "TCGA.KN.8428",
    "bcr_drug_barcode": "TCGA-KN-8428-D34187",
    "bcr_drug_uuid": "FD53289F-BFB3-419C-A907-26053E04B068",
    "form_completion_date": "2012-8-17",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 510,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 638,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "11a33d4a-4839-468f-9d61-5630586ed978",
    "patient_ID": "TCGA.KO.8404",
    "bcr_drug_barcode": "TCGA-KO-8404-D43064",
    "bcr_drug_uuid": "5052518A-3E22-436D-B3B1-8702F9B49526",
    "form_completion_date": "2013-5-9",
    "pharmaceutical_therapy_drug_name": "THALIDOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 139,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A86C2490-37DA-46A3-88E2-0B0CE21D067F",
    "patient_ID": "TCGA.UW.A7GR",
    "bcr_drug_barcode": "TCGA-UW-A7GR-D54190",
    "bcr_drug_uuid": "5B20A89E-1F30-4D80-B29F-F57E09B5BA9E",
    "form_completion_date": "2013-12-17",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 22,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 288,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A86C2490-37DA-46A3-88E2-0B0CE21D067F",
    "patient_ID": "TCGA.UW.A7GR",
    "bcr_drug_barcode": "TCGA-UW-A7GR-D54191",
    "bcr_drug_uuid": "3237FFE4-790D-4C54-8F2B-F5B75B60D901",
    "form_completion_date": "2013-12-17",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 22,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 288,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  }
]
